A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

Who May Qualify: - Has an established primary psychiatric diagnosis of schizophrenia - Clinically stable and in the residual (nonacute) phase of their illness for at least 8 weeks before screening in the judgement of the investigator - Diagnosis of schizophrenia for at least 1 year before screening - Must be in ongoing maintenance antipsychotic monotherapy on a stable medication treatment regimen for ≥ 2 months before screening, including concomitant psychotropic medications. - Male or female, aged ≥18 and ≤55 years - Has a body mass index (BMI) between 18 and 40 kg/m2 Inclusive - Must exhibit capability to comply with all protocol procedures in the judgement of the investigator - Signed and dated written willing to sign a consent form before screening in accordance with Good Clinical Practice. Who Should NOT Join This Trial: - Currently being treated with more than 1 antipsychotic at the time of screening, - A score of 2 or higher on any of the individual items of the Modified Simpson-Angus Scale (mSAS) at screening - Moderate to severe substance use disorder (other than nicotine or caffeine, but including alcohol) - Evidence of unstable medical condition Always talk to your doctor about whether this trial is right for you.